Key Points
Deerfield Management Company bought 418,538 Vera Therapeutics shares in the fourth quarter; the estimated trade size was $14.87 million.
Meanwhile, the quarter-end position value rose by $99.77 million, reflecting both the new shares held and price appreciation.
As of year's end, the fund reported holding 4,059,695 VERA shares worth $205.58 million.
Deerfield Management Company disclosed a buy of 418,538 shares of Vera Therapeutics (NASDAQ:VERA) in its February 17, 2026, SEC filing, with an estimated transaction value of $14.87 million based on the quarter’s average price.
What happened
According to a recent SEC filing, Deerfield Management Company increased its holding in Vera Therapeutics(NASDAQ:VERA) by 418,538 shares during the fourth quarter of 2025. The estimated transaction value, calculated using the period’s average closing price, was approximately $14.87 million. The quarter-end value of the stake increased by $99.77 million, reflecting both the additional shares purchased and changes in the stock price during the period.
What else to know
- This was a buy, lifting the stake to approximately 2.6% of the fund’s 13F AUM
- Top five holdings after the filing:
- NASDAQ: NUVL: $1.74 billion (25.4% of AUM)
- NASDAQ: COGT: $321.24 million (4.7% of AUM)
- NASDAQ: PRAX: $266.25 million (3.9% of AUM)
- NYSE: CNC: $265.34 million (3.9% of AUM)
- NASDAQ: VTRS: $251.57 million (3.7% of AUM)
- As of February 17, 2026, VERA shares were priced at $42.85, up approximately 50% over the past year, compared to a 19% gain in the S&P 500.
Company overview
| Metric | Value |
|---|---|
| Price (as of market close 2/17/26) | $42.85 |
| Market capitalization | $3.00 billion |
| One-year price change | 50% |
Company snapshot
- Vera’s lead product candidate is atacicept, a fusion protein in Phase IIb clinical trials for immunoglobulin A nephropathy; also developing MAU868, a monoclonal antibody in Phase 2 for BK viremia infections.
- The firm operates as a clinical-stage biotechnology company focused on developing and commercializing novel therapeutics targeting serious immunological diseases.
- It serves patients with serious immunological conditions, with a primary focus on the United States healthcare and biotechnology markets.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Brisbane, California. The company differentiates itself through the development of innovative biologic therapies targeting unmet needs in immunological diseases, leveraging advanced protein and antibody platforms. With a robust pipeline and focus on high-burden indications, Vera Therapeutics is positioned to address significant gaps in current treatment options for rare and serious conditions.
What this transaction means for investors
Vera’s flagship drug candidate, atacicept, targets two proteins known as BAFF and APRIL that drive the production of autoantibodies linked to several kidney and autoimmune diseases, and clinical progress has pushed the program to the regulatory stage. The FDA has granted priority review for the biologics license application for atacicept in IgA nephropathy and set a decision date of July 7, 2026, with a potential commercial launch expected in the middle of this year. The application follows positive Phase 3 data from the ORIGIN study program, which demonstrated meaningful reductions in proteinuria and stabilization of kidney function.
Financially, Vera is positioned to reach that milestone. The company ended 2025 with roughly $714.6 million in cash, cash equivalents, and marketable securities, which management says should provide funding through a potential approval and U.S. launch.
For long-term investors, this upcoming regulatory decision represents the inflection point that could shift Vera from a clinical-stage biotech into a commercial immunology player, so the next few months will be crucial.
Should you buy stock in Vera Therapeutics right now?
Before you buy stock in Vera Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vera Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $508,607!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,122,746!*
Now, it’s worth noting Stock Advisor’s total average return is 933% — a market-crushing outperformance compared to 188% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 13, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
